

Achillion Pharmaceuticals Investor Relations Department 300 George St. New Haven, CT 06511 United States

Visit IR website ☐ Sign-up for Email alerts ☐

4.10
4:00 PM ET Sep 21, 2017
0.01 👚 (+0.244%)
3.94 - 4.21
3.15 - 9.19
1,866,817

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... (more)

Stock Performance



Press Releases [View all]

Sep 20, 2017

Achillion to Present at the 2017 Leerink
Partners Rare Disease Roundtable Series

Sep 11, 2017

Achillion Announces Strengthening of Management Team

Sep 11, 2017

Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen

Aug 8, 2017

Achillion Reports Second Quarter 2017
Financial Results and Proof-of-Concept With
a First-in-Class, Oral Factor D Inhibitor

Aug 1, 2017

Achillion to Host Second Quarter 2017
Results Conference Call on August 8, 2017

Financial Disclosures [View all]

Second Quarter Financial Results

Feb 23, 2017

Annual Report (10-K)

Apr 17, 2017

Proxy Statement (DEF 14A)

Aug 8, 2017

Quarterly Report (10-Q)

May 4, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)